John Matthew Maris, M.D.
Professor of Pediatrics (Oncology)
Member, Hematology/Oncology Fellowship Committee, Children's Hospital of Philadelphia,
University of Pennsylvania
Co-Chair, Genetics, Genomics and Pediatric Diseases Research Affinity Group, Children's Hospital of Philadelphia
Member, Abramson Family Cancer Research Institute, University of Pennsylvania
Giulio D'Angio Endowed Chair in Neuroblastoma Research, Children's Hospital of Philadelphia
Department: Pediatrics
Graduate Group Affiliations
Contact information
The Children's Hospital of Philadelphia
Division of Oncology
Colket Translational Research Building
3501 Civic Center Boulevard #3060
4399
Philadelphia, PA 19104-4318
Division of Oncology
Colket Translational Research Building
3501 Civic Center Boulevard #3060
4399
Philadelphia, PA 19104-4318
Office: 215 590 5244
Fax: 267 426 0685
Fax: 267 426 0685
Email:
MARIS@EMAIL.CHOP.EDU
MARIS@EMAIL.CHOP.EDU
Publications
Links
Search PubMed for articles
Abramson Family Cancer Research Institute webpage.
Maris Lab Website
CCCR Faculty Profile
Search PubMed for articles
Abramson Family Cancer Research Institute webpage.
Maris Lab Website
CCCR Faculty Profile
Education:
B.S. (Biology)
Wheeling College , 1983.
M.D. (Medicine)
University of Pennsylvania, 1989.
Permanent linkB.S. (Biology)
Wheeling College , 1983.
M.D. (Medicine)
University of Pennsylvania, 1989.
Selected Publications
Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL.: Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology 40(35): 4107-4118, Dec 2022 Notes: doi: 10.1200/JCO.21.02478. Epub 2022 Jul 15.Bosse KR, Giudice AM, Lane MV, McIntyre B, Schürch PM, Pascual-Pasto G, Buongervino SN, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko ER, Daniels AA, Stundon J, Friedrichsen M, Liu X, Margolis ML, Li MM, Tierno MB, Oxnard GR, Maris JM, Mossé YP.: Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. Cancer Discovery 12(12): 2800-2819, Dec 2022 Notes: doi: 10.1158/2159-8290.CD-22-0287.
Makvandi M, Samanta M, Martorano P, Lee H, Gitto SB, Patel K, Groff D, Pogoriler J, Martinez D, Riad A, Dabagian H, Zaleski M, Taghvaee T, Xu K, Lee JY, Hou C, Farrel A, Batra V, Carlin SD, Powell DJ Jr, Mach RH, Pryma DA, Maris JM.: Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. Communications Biology 5(1): 1260, Nov 2022 Notes: doi: 10.1038/s42003-022-04209-8.
Lalchungnunga H, Hao W, Maris JM, Asgharzadeh S, Henrich KO, Westermann F, Tweddle DA, Schwalbe EC, Strathdee G.: Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma. British Journal of Cancer 127(11): 2006-2015, Nov 2022 Notes: doi: 10.1038/s41416-022-01988-z. Epub 2022 Sep 29.
Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J, Ranieri P, Tsang M, Hou C, Li Y, Pawel B, Martinez D, Vaidyanathan G, Carlin S, Pryma DA, Maris JM.: Preclinical development of [211At]meta-astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma. Clinical Cancer Research July 2022 Notes: Online ahead of print.
Krytska K, Casey CE, Pogoriler J, Martinez D, Rathi KS, Farrel A, Berko ER, Tsang M, Sano RR, Kendsersky N, Erickson SW, Teicher BA, Isse K, Saunders L, Smith MA, Maris JM, Mossé YP.: Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma. Cancer Research Communications 2(7): 616-623, July 2022 Notes: doi: 10.1158/2767-9764.crc-22-0137. Epub 2022 Jul 11.
Chang X, Liu Y, Glessner J, Hou C, Qu H, Nguyen K, Sleiman P, Lee L, Diskin SJ, Maris JM, Hakonarson H.: Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma. J Natl Cancer Inst. 114(6): 910-913, June 2022 Notes: doi: 10.1093/jnci/djac012. Online ahead of print Feb 2022.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM.: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature Nov 2021 Notes: doi: 10.1038/s41586-021-04061-6. Epub 2021 Nov 3.
Ferris MA, Smith AM, Heath SE, Duncavage EJ, Oberley MJ, Freyer D, Wynn R, Douzgou S, Maris JM, Reilly AF, Wu M, Choo F, Fiets RB, Koene S, Spencer DH, Miller CA, Shinawi M, Ley TJ.: DNMT3A Overgrowth Syndrome is associated with the development of hematopoietic malignancies in children and young adults. Blood Nov 2021.
Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H.: Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 45(8): 1075-1081, Aug 2021 Notes: Epub 2021/03/20. doi: 10.1097/PAS.0000000000001647.